Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria - TTL Representation

Raw ttl | Download


@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

 a fhir:Group ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "279340"] ; # 
  fhir:meta [
fhir:versionId [ fhir:v "4" ] ;
fhir:lastUpdated [ fhir:v "2024-11-16T19:36:32.757Z"^^xsd:dateTime ] ;
    ( fhir:profile [
fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"^^xsd:anyURI ;
fhir:link <http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition>     ] )
  ] ; # 
  fhir:text [
fhir:status [ fhir:v "extensions" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Group 279340</b></p><a name=\"279340\"> </a><a name=\"hc279340\"> </a><a name=\"279340-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 4; Last updated: 2024-11-16 19:36:32+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-conceptual-cohort-definition.html\">ConceptualCohortDefinition</a></p></div><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>Artifact related artifact</b>: No display for RelatedArtifact  (type: cite-as; citation: CohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 279340. Revised 2024-09-29. Available at: https://fevir.net/resources/Group/279340. Computable resource at: https://fevir.net/resources/Group/279340.)</p><p><b>url</b>: <a href=\"https://fevir.net/resources/Group/279340\">https://fevir.net/resources/Group/279340</a></p><p><b>identifier</b>: FEvIR Object Identifier/https://fevir.net/FOI/279340</p><p><b>title</b>: ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria\na. T1DM-specific criteria\n..i. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria\n..ii. have been on the following daily insulin therapy for at least 1 year\n...1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or\n...2) continuous subcutaneous insulin infusion (CSII)\n..iii. are between 18 and 64 years old at the time of informed consent\n..iv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening\nb. T2DM-specific criteria\n..i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\n..ii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n...1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n...2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\n..iii. are between 20 and 70 years old at the time of informed consent\n..iv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening</p>\n</div><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>membership</b>: Conceptual</p><p><b>combinationMethod</b>: Any of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Defined by Reference</span></p><p><b>value</b>: <a href=\"Group-279347.html\">CohortDefinition: T1DM-specific criteria</a></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>T1DM-specific criteria\ni. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria\nii. have been on the following daily insulin therapy for at least 1 year\n..1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or...2) continuous subcutaneous insulin infusion (CSII)\niii. are between 18 and 64 years old at the time of informed consent\niv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening</p>\n</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Defined by Reference</span></p><p><b>value</b>: <a href=\"Group-279346.html\">CohortDefinition: T2DM-specific criteria</a></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>T2DM-specific criteria\ni. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\nii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\niii. are between 20 and 70 years old at the time of informed consent\niv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening</p>\n</div></blockquote></div>"
  ] ; # 
  fhir:extension ( [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-author"^^xsd:anyURI ] ;
fhir:value [
a fhir:ContactDetail ;
fhir:name [ fhir:v "Brian S. Alper" ]     ]
  ] [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact"^^xsd:anyURI ] ;
fhir:value [
a fhir:RelatedArtifact ;
fhir:type [ fhir:v "cite-as" ] ;
fhir:citation [ fhir:v "CohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 279340. Revised 2024-09-29. Available at: https://fevir.net/resources/Group/279340. Computable resource at: https://fevir.net/resources/Group/279340." ]     ]
  ] ) ; # 
  fhir:url [ fhir:v "https://fevir.net/resources/Group/279340"^^xsd:anyURI] ; # 
  fhir:identifier ( [
fhir:type [
      ( fhir:coding [
fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ;
fhir:code [ fhir:v "ACSN" ] ;
fhir:display [ fhir:v "Accession ID" ]       ] ) ;
fhir:text [ fhir:v "FEvIR Object Identifier" ]     ] ;
fhir:system [ fhir:v "urn:ietf:rfc:3986"^^xsd:anyURI ] ;
fhir:value [ fhir:v "https://fevir.net/FOI/279340" ] ;
fhir:assigner [
fhir:display [ fhir:v "Computable Publishing LLC" ]     ]
  ] ) ; # 
  fhir:title [ fhir:v "ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria"] ; # 
  fhir:status [ fhir:v "active"] ; # 
  fhir:publisher [ fhir:v "Computable Publishing LLC"] ; # 
  fhir:contact ( [
    ( fhir:telecom [
fhir:system [ fhir:v "email" ] ;
fhir:value [ fhir:v "support@computablepublishing.com" ]     ] )
  ] ) ; # 
  fhir:description [ fhir:v "Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria\na. T1DM-specific criteria\n..i. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria\n..ii. have been on the following daily insulin therapy for at least 1 year\n...1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or\n...2) continuous subcutaneous insulin infusion (CSII)\n..iii. are between 18 and 64 years old at the time of informed consent\n..iv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening\nb. T2DM-specific criteria\n..i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\n..ii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n...1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n...2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\n..iii. are between 20 and 70 years old at the time of informed consent\n..iv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening"] ; # 
  fhir:copyright [ fhir:v "https://creativecommons.org/licenses/by-nc-sa/4.0/"] ; # 
  fhir:membership [ fhir:v "conceptual"] ; # 
  fhir:combinationMethod [ fhir:v "any-of"] ; # 
  fhir:characteristic ( [
fhir:code [
fhir:text [ fhir:v "Defined by Reference" ]     ] ;
fhir:value [
a fhir:Reference ;
fhir:reference [ fhir:v "Group/279347" ] ;
fhir:type [ fhir:v "Group"^^xsd:anyURI ] ;
fhir:display [ fhir:v "CohortDefinition: T1DM-specific criteria" ]     ] ;
fhir:exclude [ fhir:v "false"^^xsd:boolean ] ;
fhir:description [ fhir:v "T1DM-specific criteria\ni. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria\nii. have been on the following daily insulin therapy for at least 1 year\n..1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or...2) continuous subcutaneous insulin infusion (CSII)\niii. are between 18 and 64 years old at the time of informed consent\niv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening" ]
  ] [
fhir:code [
fhir:text [ fhir:v "Defined by Reference" ]     ] ;
fhir:value [
a fhir:Reference ;
fhir:reference [ fhir:v "Group/279346" ] ;
fhir:type [ fhir:v "Group"^^xsd:anyURI ] ;
fhir:display [ fhir:v "CohortDefinition: T2DM-specific criteria" ]     ] ;
fhir:exclude [ fhir:v "false"^^xsd:boolean ] ;
fhir:description [ fhir:v "T2DM-specific criteria\ni. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\nii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\niii. are between 20 and 70 years old at the time of informed consent\niv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening" ]
  ] ) . #